The kidney and lipids: preface

[1]  David C. Wheeler,et al.  KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease Foreword , 2013 .

[2]  K. Hiromura,et al.  Nephrotic syndrome caused by immune-mediated acquired LCAT deficiency. , 2013, Journal of the American Society of Nephrology : JASN.

[3]  M. Rocco,et al.  Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  G. Genovese,et al.  Population-based risk assessment of APOL1 on renal disease. , 2011, Journal of the American Society of Nephrology : JASN.

[5]  M. Landray,et al.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial , 2011, The Lancet.

[6]  T. Leren,et al.  Lecithin:Cholesterol Acyltransferase (LCAT) Deficiency: Renal Lesions with Early Graft Recurrence , 2011, Ultrastructural pathology.

[7]  O. Dekkers,et al.  Genetic associations in diabetic nephropathy: a meta-analysis , 2010, Diabetologia.

[8]  C. Winkler,et al.  Association of Trypanolytic ApoL1 Variants with Kidney Disease in African Americans , 2010, Science.

[9]  Gert Mayer,et al.  Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. , 2009, The New England journal of medicine.

[10]  N. Yorioka,et al.  Beneficial effect of low-density lipoprotein apheresis (LDL-A) on refractory nephrotic syndrome (NS) due to focal glomerulosclerosis (FGS). , 2007, Clinical nephrology.

[11]  R. Trevisan,et al.  Lipids and renal disease. , 2006, Journal of the American Society of Nephrology : JASN.

[12]  S. Oikawa,et al.  Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  A. Hartmann,et al.  Long‐term Cardiac Outcomes in Renal Transplant Recipients Receiving Fluvastatin: The ALERT Extension Study , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  W. März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.

[15]  I. Holme,et al.  Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial , 2003, The Lancet.

[16]  Takashi Suzuki,et al.  Virus-mediated Transduction of Apolipoprotein E (ApoE)-Sendai Develops Lipoprotein Glomerulopathy in ApoE-deficient Mice* , 2000, The Journal of Biological Chemistry.

[17]  Z. Varghese,et al.  LIPID NEPHROTOXICITY IN CHRONIC PROGRESSIVE GLOMERULAR AND TUBULO-INTERSTITIAL DISEASE , 1982, The Lancet.

[18]  Baig Ar,et al.  Sex-chromatin values in rat epithelium. , 1967 .

[19]  Brenda R. Hemmelgarn,et al.  Notice , 2012, Kidney International Supplements.

[20]  R. Garrick.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial , 2011 .

[21]  Donald W. Bowden,et al.  Association of Trypanolytic ApoL 1 Variants with Kidney Disease in African Americans , 2010 .

[22]  R. Berg,et al.  A Systematic Review and Meta-analysis , 2010 .

[23]  S. Sasayama,et al.  Does LDL-apheresis in steroid-resistant nephrotic syndrome affect prognosis? , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[24]  P. Kimmelstiel,et al.  Intercapillary Lesions in the Glomeruli of the Kidney. , 1936, The American journal of pathology.